8
Jun
2016
The 5 Deep State Scenarios of Donald Trump

I’ve never really bought this “loose canon / anti-establishment” candidate schtick. It looks like yet another con-job on the masses….The question is, which con is being run?

It truly boggles the mind that we are living in a world where we are facing an election for the world’s most important spokesmodel and the candidates will be Donald Trump (narcissistic, serial bankrupt) and Hillary Clinton (known racketeer and influence peddler).…

Read More
0 Comments
8
Jun
2016
Charles Hugh Smith talks about A Radically Beneficial World
To kick off a new podcast series introducing our new line of audiobooks, Charles Hugh Smith joins Mark Jeftovic to discuss his new book, A Radically Beneficial World: Automation, Technology and Creating Jobs for All

Read More
0 Comments
7
Jun
2016
Conversation with Charles Hugh Smith: A Radically Beneficial World
We kick off our podcast series in conversation with Charles Hugh Smith, author of A Radically Beneficial World. Read More
0 Comments
7
Jun
2016
India: Funding rounds are revenue after all
  The tag line for this site is “True Fact: Funding rounds are not revenue”, except in India, where a new tax code law has deemed that funding rounds that take place “at above fair value” are indeed income. The new rule applies to startups that have undergone a down round. If the preceding round was not from a VC firm registered with the Indian securities regulator (in other words it was from an angel... Read More
0 Comments
3
Jun
2016
Glassdoor CEO redefines down-round as “modest up round”.
broken-front-door.jpg In a $40 million dollar funding round at a lower share price (a.k.a “a down round”) Glassdoor CEO went on record to say “We view this as a slight up round” (I guess you can add diluting shares to inflate market cap to the alchemical bag of tricks in this wonderful New Economy). Still, with shares down 6.3% in this round, they are still clobbering their publicly traded Unicorn peers such as LinkedIn and Yelp.... Read More
0 Comments
31
May
2016
Bay area biotech StemCells to wind down.
implosion.jpg They were working on a spinal chord treatment but their clinical trials have failed. Bay area biotech “StemCells” (I was surprised they didn’t “invest” in the .com version of their name) which was publicly traded  will wind down operations. They are hoping to see what can be salvaged for investors and skirt a 100% loss. At their peak: $74 million market cap. Now, not so much. ($6 million) They also raised 32 million in two... Read More
0 Comments